PTEN and cancer: These findings demonstrate a molecular mechanism linking PTEN loss and STAT3 activation in cancer and suggest that PI3Kβ controls immune escape in PTEN-mutation tumors, providing a rationale for combining PI3Kβ inhibitors with immunotherapy.